Inotiv (NOTV) Projected to Release Quarterly Earnings on Wednesday

Inotiv (NASDAQ:NOTV) is expected to be announcing its Q3 2026 resultson Wednesday, August 5th. Analysts expect Inotiv to post earnings of ($0.47) per share and revenue of $136.6840 million for the quarter. Interested persons may visit the the company’s upcoming Q3 2026 earning results page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

Inotiv (NASDAQ:NOTV) last issued its earnings results on Monday, May 11th. The company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.30). The firm had revenue of $117.65 million during the quarter, compared to analyst estimates of $124.74 million. Inotiv had a negative net margin of 17.14% and a negative return on equity of 56.77%.

Inotiv Price Performance

NASDAQ NOTV opened at $0.01 on Monday. The business’s 50-day simple moving average is $0.06 and its 200-day simple moving average is $0.25. The firm has a market capitalization of $387,256.80, a P/E ratio of -0.00 and a beta of 3.77. Inotiv has a 1-year low of $0.08 and a 1-year high of $2.95.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Inotiv in a research note on Friday, April 10th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $1.50.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Virtu Financial LLC raised its stake in Inotiv by 313.6% during the fourth quarter. Virtu Financial LLC now owns 66,331 shares of the company’s stock worth $37,000 after acquiring an additional 50,293 shares during the period. Balyasny Asset Management L.P. grew its stake in Inotiv by 49.3% during the 4th quarter. Balyasny Asset Management L.P. now owns 1,471,849 shares of the company’s stock worth $827,000 after buying an additional 486,113 shares during the last quarter. Squarepoint Ops LLC increased its position in Inotiv by 304.2% in the fourth quarter. Squarepoint Ops LLC now owns 59,202 shares of the company’s stock worth $33,000 after buying an additional 44,554 shares during the period. Voleon Capital Management LP acquired a new stake in Inotiv in the third quarter worth $205,000. Finally, Wexford Capital LP bought a new stake in Inotiv in the third quarter valued at $127,000. Institutional investors and hedge funds own 18.17% of the company’s stock.

About Inotiv

Inotiv, Inc, formerly known as Bioanalytical Systems, Inc (NASDAQ: NOTV), is a global contract research organization (CRO) specializing in preclinical drug discovery, development and testing services. The company partners with pharmaceutical, biotech and medical device companies to advance candidate molecules through early‐stage research and safety assessment. Inotiv’s integrated platform spans in vivo and in vitro pharmacology, drug metabolism and pharmacokinetics (DMPK), toxicology, pathology and bioanalysis.

The company’s core service offerings include discovery pharmacology, safety assessment toxicology, pathology, bioanalysis and regulatory support.